| A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology KP Guillen, M Fujita, AJ Butterfield, SD Scherer, MH Bailey, Z Chu, ... Nature cancer 3 (2), 232-250, 2022 | 173 | 2022 |
| Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models A Bahreini, Z Li, P Wang, KM Levine, N Tasdemir, L Cao, HM Weir, ... Breast Cancer Research 19, 1-10, 2017 | 150 | 2017 |
| Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance LA Martin, R Ribas, N Simigdala, E Schuster, S Pancholi, T Tenev, ... Nature communications 8 (1), 1865, 2017 | 144 | 2017 |
| Comprehensive phenotypic characterization of human invasive lobular carcinoma cell lines in 2D and 3D cultures N Tasdemir, EA Bossart, Z Li, L Zhu, MJ Sikora, KM Levine, BM Jacobsen, ... Cancer research 78 (21), 6209-6222, 2018 | 69 | 2018 |
| Tumor-secreted anterior gradient-2 binds to VEGF and FGF2 and enhances their activities by promoting their homodimerization H Guo, Q Zhu, X Yu, SB Merugu, HB Mangukiya, N Smith, Z Li, B Zhang, ... Oncogene 36 (36), 5098-5109, 2017 | 56 | 2017 |
| Untangling the web of intratumour heterogeneity Z Li, M Seehawer, K Polyak Nature cell biology 24 (8), 1192-1201, 2022 | 47 | 2022 |
| Anterior gradient 2 is a binding stabilizer of hypoxia inducible factor‐1α that enhances CoCl2‐induced doxorubicin resistance in breast cancer cells Z Li, Q Zhu, L Hu, H Chen, Z Wu, D Li Cancer science 106 (8), 1041-1049, 2015 | 44 | 2015 |
| Estrogen receptor alpha mutations in breast cancer cells cause gene expression changes through constant activity and secondary effects S Arnesen, Z Blanchard, MM Williams, KC Berrett, Z Li, S Oesterreich, ... Cancer research 81 (3), 539-551, 2021 | 43 | 2021 |
| Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells Z Li, KM Levine, A Bahreini, P Wang, D Chu, BH Park, S Oesterreich, ... Endocrinology 159 (1), 285-296, 2018 | 42 | 2018 |
| ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation Z Li, O McGinn, Y Wu, A Bahreini, NM Priedigkeit, K Ding, S Onkar, ... Nature Communications 13 (1), 2011, 2022 | 40 | 2022 |
| Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis Z Li, Y Wu, ME Yates, N Tasdemir, A Bahreini, J Chen, KM Levine, ... Cancer research 82 (7), 1321-1339, 2022 | 40 | 2022 |
| JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States LE Stevens, G Peluffo, X Qiu, D Temko, A Fassl, Z Li, A Trinh, ... Cancer research 83 (2), 264-284, 2023 | 37 | 2023 |
| Steroid hormone receptor and infiltrating immune cell status reveals therapeutic vulnerabilities of ESR1-mutant breast cancer MM Williams, NS Spoelstra, S Arnesen, KI O'Neill, JL Christenson, ... Cancer research 81 (3), 732-746, 2021 | 35 | 2021 |
| Anterior Gradient-2 monoclonal antibody inhibits lung cancer growth and metastasis by upregulating p53 pathway and without exerting any toxicological effects: a preclinical study H Negi, SB Merugu, HB Mangukiya, Z Li, B Zhou, Q Sehar, S Kamle, ... Cancer letters 449, 125-134, 2019 | 33 | 2019 |
| Binding of anterior gradient 2 and estrogen receptor-α: dual critical roles in enhancing fulvestrant resistance and IGF-1-induced tumorigenesis of breast cancer Z Li, Q Zhu, H Chen, L Hu, H Negi, Y Zheng, Y Ahmed, Z Wu, D Li Cancer letters 377 (1), 32-43, 2016 | 31 | 2016 |
| Induction of anterior gradient 2 (AGR2) plays a key role in insulin-like growth factor-1 (IGF-1)-induced breast cancer cell proliferation and migration Z Li, Z Wu, H Chen, Q Zhu, G Gao, L Hu, H Negi, S Kamle, D Li Medical Oncology 32, 1-12, 2015 | 31 | 2015 |
| An immune-humanized patient-derived xenograft model of estrogen-independent, hormone receptor positive metastatic breast cancer SD Scherer, AI Riggio, F Haroun, YS DeRose, HA Ekiz, M Fujita, J Toner, ... Breast Cancer Research 23, 1-18, 2021 | 30 | 2021 |
| Clinically observed estrogen receptor alpha mutations within the ligand-binding domain confer distinguishable phenotypes S Jia, MT Miedel, M Ngo, R Hessenius, N Chen, P Wang, A Bahreini, Z Li, ... Oncology 94 (3), 176-189, 2018 | 25 | 2018 |
| Sal‐like protein 2 upregulates p16 expression through a proximal promoter element Z Wu, K Cheng, L Shi, Z Li, H Negi, G Gao, S Kamle, D Li Cancer Science 106 (3), 253-261, 2015 | 20 | 2015 |
| Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer Z Li, NS Spoelstra, MJ Sikora, SB Sams, A Elias, JK Richer, AV Lee, ... NPJ Breast Cancer 8 (1), 62, 2022 | 12 | 2022 |
